Skip to content
CNS Clinical Research

Nashville, Tennessee

CNS clinical trials in Nashville, TN

46 CNS studies are recruiting participants at sites in Nashville as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Nashville at a glance

  • 46 studies are recruiting at a site in Nashville.
  • By phase: Early Phase 1 (1), Phase 1 (1), Phase 2 (5), Phase 3 (17), Phase 4 (2), No phase (11), Observational (9). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (24), industry (22).
  • By research area: Parkinson's Disease (17), Depression (9), Migraine (7), Epilepsy (6), Schizophrenia (5), Multiple Sclerosis (2).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Nashville

Basic details from each study's public record (the 30 most recently updated of 46). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Vanderbilt Breast Center at One Hundred Oaks
    Registry record
    NCT06748222 · updated
  2. To Improve Depressive Symptoms Using a Web-App

    • No phase
    • Ages 40 to 60
    • Female participants
    Sponsor
    Vanderbilt University
    Study site
    Vanderbilt University
    Registry record
    NCT05405803 · updated
  3. Cancer Pain Management Using a Web-based Intervention

    • No phase
    • Ages 18 and older
    • Female participants
    Sponsor
    Vanderbilt University
    Study site
    Vanderbilt University
    Registry record
    NCT06085313 · updated
  4. CBT Enhanced With Social Cognitive Training vs. CBT Only With Depressed Youth

    • No phase
    • Ages 13 to 17
    • All sexes
    Sponsor
    Vanderbilt University
    Study site
    Judy Garber
    Registry record
    NCT05456035 · updated
  5. PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Yale University
    Study site
    Athena Care
    Registry record
    NCT06713616 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Nashville, TN on ClinicalTrials.gov.

Schizophrenia studies recruiting in Nashville

  1. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Access Clinical Trials
    Registry record
    NCT06229210 · updated
  2. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Vanderbilt Psychiatric Hospital
    Registry record
    NCT06585787 · updated
  3. Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With Psychotherapy

    • No phase
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanderbilt University Medical Center
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT06835556 · updated
  4. The Parasite and Infestation Study

    • Observational
    • Ages 18 to 70
    • All sexes
    Sponsor
    Vanderbilt University Medical Center
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT07849907 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Nashville, TN on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Nashville

  1. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    SCRI Oncology Partners ( Site 7004) · Tennessee Oncology ( Site 0018)
    Registry record
    NCT06841354 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Nashville General Hospital ( Site 0017) · SCRI Oncology Partners ( Site 7005) · Vanderbilt-Ingram Cancer Center ( Site 0038)
    Registry record
    NCT06966700 · updated
  3. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Elliston Place Medical Oncology & Hematology ( Site 0215)
    Registry record
    NCT06623422 · updated
  4. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT07174310 · updated
  5. A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    • Phase 3
    • Ages 45 to 75
    • All sexes
    Sponsor
    BlueRock Therapeutics
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT06944522 · updated
  6. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    Vanderbilt University
    Registry record
    NCT06680830 · updated
  7. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    • Phase 2
    • Ages 30 to 80
    • All sexes
    Sponsor
    Appello Pharmaceuticals, Inc.
    Study site
    Vanderbilt University Medical Center (Site #204)
    Registry record
    NCT07432958 · updated
  8. Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Vanderbilt University Medical Center
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT01734122 · updated
  9. Parkinson's Foundation PD GENEration Genetic Registry

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Parkinson's Foundation
    Study site
    Vanderbilt University
    Registry record
    NCT04994015 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Nashville, TN on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Nashville

  1. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated
  2. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Vanderbilt Breast Center at One Hundred Oaks
    Registry record
    NCT07225504 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Nashville, TN on ClinicalTrials.gov.

Epilepsy studies recruiting in Nashville

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07594119 · updated
  2. A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT05716100 · updated
  3. RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT06798896 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Nashville, TN on ClinicalTrials.gov.

Migraine studies recruiting in Nashville

  1. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    • Phase 4
    • Ages 18 to 70
    • All sexes
    Sponsor
    Mayo Clinic
    Study site
    Vanderbilt Medical Center
    Registry record
    NCT06972056 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Access Clinical Trials, Inc · Clinical Research Associates, Inc.
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Access Clinical Trials Inc · Clinical Research Associates, Inc.
    Registry record
    NCT07674654 · updated
  4. A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Access Clinical Trials Inc /ID# 270280
    Registry record
    NCT06810505 · updated
  5. Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Aspeya, Inc.
    Study site
    Clinical Research Associates, Inc.
    Registry record
    NCT07646613 · updated
  6. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Access Clinical Trials, Inc. /ID# 248532
    Registry record
    NCT05711394 · updated
  7. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Access Clinical Trials, Inc. /ID# 228002
    Registry record
    NCT05125302 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Nashville, TN on ClinicalTrials.gov.

Ask about studies near Nashville

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call